Is Bloom Energy Flying Under the Radar?
Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…
Sell
32
ASND Quote, Financials, Valuation and Earnings
Last price:
$170.13
Seasonality move
:
11.4%
Day range:
$169.52 - $179.96
52-week range:
$111.09 - $183.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
25.30x
P/B ratio:
--
Volume:
617.7K
Avg. volume:
422.4K
1-year change:
24.45%
Market cap:
$10.3B
Revenue:
$393.6M
EPS (TTM):
-$6.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ASND
Ascendis Pharma AS
|
$167.5M | -$1.50 | 234.66% | -62.75% | $234.32 |
|
ALNY
Alnylam Pharmaceuticals
|
$648.2M | $0.10 | -3.52% | -58.59% | $332.06 |
|
ARDX
Ardelyx
|
$82.5M | -$0.14 | 12.93% | -95.54% | $10.91 |
|
AUTL
Autolus Therapeutics PLC
|
$12.9M | -$0.23 | -80.39% | -10.73% | $9.86 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
TGTX
TG Therapeutics
|
$145.3M | $0.28 | 101.13% | 653.48% | $40.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ASND
Ascendis Pharma AS
|
$169.90 | $234.32 | $10.3B | -- | $0.00 | 0% | 25.30x |
|
ALNY
Alnylam Pharmaceuticals
|
$320.53 | $332.06 | $41.8B | -- | $0.00 | 0% | 17.55x |
|
ARDX
Ardelyx
|
$4.41 | $10.91 | $1.1B | -- | $0.00 | 0% | 2.89x |
|
AUTL
Autolus Therapeutics PLC
|
$2.41 | $9.86 | $641.4M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.05 | $104.00 | $288.9K | -- | $0.00 | 0% | -- |
|
TGTX
TG Therapeutics
|
$37.91 | $40.50 | $6B | 157.96x | $0.00 | 0% | 15.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ASND
Ascendis Pharma AS
|
128.87% | 0.160 | 9.75% | 0.67x |
|
ALNY
Alnylam Pharmaceuticals
|
89.88% | 0.837 | 2.91% | 2.84x |
|
ARDX
Ardelyx
|
50.95% | -0.143 | 12.88% | 3.43x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.256 | -- | 8.74x |
|
NCNA
NuCana PLC
|
-- | -1.015 | -- | -- |
|
TGTX
TG Therapeutics
|
-- | -0.654 | -- | 2.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ASND
Ascendis Pharma AS
|
$87.8M | -$106M | -59.13% | -880.05% | -48.32% | -$15.8M |
|
ALNY
Alnylam Pharmaceuticals
|
$523.1M | $18.1M | -26.39% | -- | -0.5% | -$127.3M |
|
ARDX
Ardelyx
|
$61.8M | -$36.3M | -19.51% | -34.68% | -45.91% | -$38.8M |
|
AUTL
Autolus Therapeutics PLC
|
-$9M | -$65.2M | -49.92% | -49.92% | -643.43% | -$83.8M |
|
NCNA
NuCana PLC
|
-- | -$3.5M | -- | -- | -- | -$4M |
|
TGTX
TG Therapeutics
|
$105.3M | $8.6M | 11.64% | 19.78% | 10.12% | -$28.7M |
Ascendis Pharma AS vs. Competitors
-
Which has Higher Returns ASND or ALNY?
Alnylam Pharmaceuticals has a net margin of -93.73% compared to Ascendis Pharma AS's net margin of -9.67%. Ascendis Pharma AS's return on equity of -880.05% beat Alnylam Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ASNDAscendis Pharma AS82.65% -$1.66 $711.6M ALNYAlnylam Pharmaceuticals88.04% -$0.44 $1.1B -
What do Analysts Say About ASND or ALNY?
Ascendis Pharma AS has a consensus price target of $234.32, signalling upside risk potential of 37.92%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $332.06 which suggests that it could grow by 3.6%. Given that Ascendis Pharma AS has higher upside potential than Alnylam Pharmaceuticals, analysts believe Ascendis Pharma AS is more attractive than Alnylam Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ASNDAscendis Pharma AS13 0 0 ALNYAlnylam Pharmaceuticals14 7 1 -
Is ASND or ALNY More Risky?
Ascendis Pharma AS has a beta of 0.376, which suggesting that the stock is 62.4% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.226, suggesting its less volatile than the S&P 500 by 77.386%.
-
Which is a Better Dividend Stock ASND or ALNY?
Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASND or ALNY?
Ascendis Pharma AS quarterly revenues are $106.2M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Ascendis Pharma AS's net income of -$99.6M is lower than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 25.30x versus 17.55x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASNDAscendis Pharma AS25.30x -- $106.2M -$99.6M ALNYAlnylam Pharmaceuticals17.55x -- $594.2M -$57.5M
-
Which has Higher Returns ASND or ARDX?
Ardelyx has a net margin of -93.73% compared to Ascendis Pharma AS's net margin of -55.52%. Ascendis Pharma AS's return on equity of -880.05% beat Ardelyx's return on equity of -34.68%.
Company Gross Margin Earnings Per Share Invested Capital ASNDAscendis Pharma AS82.65% -$1.66 $711.6M ARDXArdelyx83.4% -$0.17 $297M -
What do Analysts Say About ASND or ARDX?
Ascendis Pharma AS has a consensus price target of $234.32, signalling upside risk potential of 37.92%. On the other hand Ardelyx has an analysts' consensus of $10.91 which suggests that it could grow by 147.37%. Given that Ardelyx has higher upside potential than Ascendis Pharma AS, analysts believe Ardelyx is more attractive than Ascendis Pharma AS.
Company Buy Ratings Hold Ratings Sell Ratings ASNDAscendis Pharma AS13 0 0 ARDXArdelyx8 1 0 -
Is ASND or ARDX More Risky?
Ascendis Pharma AS has a beta of 0.376, which suggesting that the stock is 62.4% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.
-
Which is a Better Dividend Stock ASND or ARDX?
Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASND or ARDX?
Ascendis Pharma AS quarterly revenues are $106.2M, which are larger than Ardelyx quarterly revenues of $74.1M. Ascendis Pharma AS's net income of -$99.6M is lower than Ardelyx's net income of -$41.1M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 25.30x versus 2.89x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASNDAscendis Pharma AS25.30x -- $106.2M -$99.6M ARDXArdelyx2.89x -- $74.1M -$41.1M
-
Which has Higher Returns ASND or AUTL?
Autolus Therapeutics PLC has a net margin of -93.73% compared to Ascendis Pharma AS's net margin of -781.13%. Ascendis Pharma AS's return on equity of -880.05% beat Autolus Therapeutics PLC's return on equity of -49.92%.
Company Gross Margin Earnings Per Share Invested Capital ASNDAscendis Pharma AS82.65% -$1.66 $711.6M AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M -
What do Analysts Say About ASND or AUTL?
Ascendis Pharma AS has a consensus price target of $234.32, signalling upside risk potential of 37.92%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 308.94%. Given that Autolus Therapeutics PLC has higher upside potential than Ascendis Pharma AS, analysts believe Autolus Therapeutics PLC is more attractive than Ascendis Pharma AS.
Company Buy Ratings Hold Ratings Sell Ratings ASNDAscendis Pharma AS13 0 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is ASND or AUTL More Risky?
Ascendis Pharma AS has a beta of 0.376, which suggesting that the stock is 62.4% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.813, suggesting its more volatile than the S&P 500 by 81.299%.
-
Which is a Better Dividend Stock ASND or AUTL?
Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASND or AUTL?
Ascendis Pharma AS quarterly revenues are $106.2M, which are larger than Autolus Therapeutics PLC quarterly revenues of $9M. Ascendis Pharma AS's net income of -$99.6M is lower than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 25.30x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASNDAscendis Pharma AS25.30x -- $106.2M -$99.6M AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M
-
Which has Higher Returns ASND or NCNA?
NuCana PLC has a net margin of -93.73% compared to Ascendis Pharma AS's net margin of --. Ascendis Pharma AS's return on equity of -880.05% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ASNDAscendis Pharma AS82.65% -$1.66 $711.6M NCNANuCana PLC-- -$0.63 -- -
What do Analysts Say About ASND or NCNA?
Ascendis Pharma AS has a consensus price target of $234.32, signalling upside risk potential of 37.92%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 217929.35%. Given that NuCana PLC has higher upside potential than Ascendis Pharma AS, analysts believe NuCana PLC is more attractive than Ascendis Pharma AS.
Company Buy Ratings Hold Ratings Sell Ratings ASNDAscendis Pharma AS13 0 0 NCNANuCana PLC0 1 0 -
Is ASND or NCNA More Risky?
Ascendis Pharma AS has a beta of 0.376, which suggesting that the stock is 62.4% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.
-
Which is a Better Dividend Stock ASND or NCNA?
Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASND or NCNA?
Ascendis Pharma AS quarterly revenues are $106.2M, which are larger than NuCana PLC quarterly revenues of --. Ascendis Pharma AS's net income of -$99.6M is lower than NuCana PLC's net income of -$3.1M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 25.30x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASNDAscendis Pharma AS25.30x -- $106.2M -$99.6M NCNANuCana PLC-- -- -- -$3.1M
-
Which has Higher Returns ASND or TGTX?
TG Therapeutics has a net margin of -93.73% compared to Ascendis Pharma AS's net margin of 4.19%. Ascendis Pharma AS's return on equity of -880.05% beat TG Therapeutics's return on equity of 19.78%.
Company Gross Margin Earnings Per Share Invested Capital ASNDAscendis Pharma AS82.65% -$1.66 $711.6M TGTXTG Therapeutics87.14% $0.03 $237.3M -
What do Analysts Say About ASND or TGTX?
Ascendis Pharma AS has a consensus price target of $234.32, signalling upside risk potential of 37.92%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 6.83%. Given that Ascendis Pharma AS has higher upside potential than TG Therapeutics, analysts believe Ascendis Pharma AS is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ASNDAscendis Pharma AS13 0 0 TGTXTG Therapeutics5 1 0 -
Is ASND or TGTX More Risky?
Ascendis Pharma AS has a beta of 0.376, which suggesting that the stock is 62.4% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.
-
Which is a Better Dividend Stock ASND or TGTX?
Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASND or TGTX?
Ascendis Pharma AS quarterly revenues are $106.2M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Ascendis Pharma AS's net income of -$99.6M is lower than TG Therapeutics's net income of $5.1M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 157.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 25.30x versus 15.78x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASNDAscendis Pharma AS25.30x -- $106.2M -$99.6M TGTXTG Therapeutics15.78x 157.96x $120.9M $5.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
55
TLN alert for Jul 19
Talen Energy [TLN] is up 24.44% over the past day.
Sell
48
CRSP alert for Jul 19
CRISPR Therapeutics AG [CRSP] is up 18.22% over the past day.
Buy
83
SOC alert for Jul 19
Sable Offshore [SOC] is up 11.86% over the past day.
